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The carcinoembryonic antigen (CEA) gene 
family belongs to the immunoglobulin super- 
gene family and can be divided into two main 
subgroups based on sequence comparisons. 
In humans it is clustered on the long arm of 
chromosome 19 and consists of approxi- 
mately 20 genes. The CEA subgroup genes 
code for CEA and its classical crossreacting 
antigens, which are mainly membrane-bound, 
whereas the other subgroup genes encode 
the pregnancy-specific glycoproteins (PSG), 
which are secreted. Splice variants of indi- 
vidual genes and differential post-translational 
modifications of the resulting proteins, e.g., 
by glycosylation, indicate a high complexity 
in the number of putative CEA-related mole- 
cules. So far, only a limited number of CEA- 
related antigens in humans have been 
unequivocally assigned to a specific gene. 
Rodent CEA-related genes reveal a high 
sequence divergence and, in part, a com- 
pletely different domain organization than the 
human CEA gene family, making it difficult 
to determine individual gene counterparts. 
However, rodent CEA-related genes can be 
assigned to human subgroups based on sim- 
ilarity of expression patterns, which is char- 
acteristic for the subgroups. Various functions 
have been determined for members of the 
CEA subgroup in vitro, including cell adhe- 
sion, bacterial binding, an accessory role for 
collagen binding or ecto-ATPases activity. 
Based on all that is known so far on its bio- 
logy, the clinical outlook for the CEA family 
has been reassessed. 
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INTRODUCTION 
With improvements in modem medicine, life expectancy 
is continuously increasing. However, this prolongation of life, 
together with the many negative influences of modem soci- 
ety, has also led to an increase in the number of so-called 
civilization illnesses. In many industrial countries, after heart 
disease, cancer is one of the major causes of death, and lung 
and colonic cancers are the most prevalent types of malig- 
nancy (1). Although cancer is not a new disease, certain forms 
have dramatically increased due to bad habits: e.g., exces- 
sive smoking has made lung cancer a major problem and fat- 
rich, low-fiber diets correlate with an increase in colonic 
cancer. The inherent fear that a tumor may be discovered deters 
many people from having regular medical examinations, with 
the result that therapy may often come too late. Improved meth- 
ods have to be developed whereby malignancies can be rec- 
ognized earlier and treated more specifically as well as more 
efficiently. For example, the targeting of cytotoxic substances 
could help to decrease the dosage and reduce the side effects 
and should result in higher concentrations at the tumor. In 
order to achieve this, differences between tumorous and nor- 
mal tissues have to be exploited. 
Earlier studies revealed the existence of certain molecules 
which were apparently only present in tumors and were later 
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named tumor markers (reviewed in 2). Subsequent investiga- 
tions showed that tumor markers are not tumor-specific (apart 
from possible mutant molecular forms, viral proteins, or the 
idiotypic regions of antigen receptors in B- and T-cell lym- 
phomas) and their potential clinical application was ques- 
tioned. This holds true for the carcinoembryonic antigen 
(CEA), which was first described by Gold and Freedman and 
independently by von Kleist and Burtin to be present in colonic 
tumors and in fetal gut, but not in normal colonic mucosa 
(3-5). However, CEA was later found in normal body fluids 
and in normal colonic mucosa (6-9), although tumor CEA 
concentrations are on average >60 times higher (10). A possi- 
ble complication for the clinical application of CEA is the 
existence of a number of closely related crossreacting anti- 
gens, which show variable expression patterns, and are found 
in a variety of normal tissues (summarized in 11). 
Nevertheless, measurement of the CEA serum concentra- 
tions is an important parameter in the monitoring of patients 
following tumor resection (reviewed in 12,13). In fact, ele- 
vated CEA levels have also been found in other tumors of 
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TABLE 1. Classification of the Human CEA Gene Familv epithelial origin, e.g., breast, lung, pancreas, etc. (reviewed 
in 12,14). With the development of monospecific anti-CEA 
monoclonal antibodies (reviewed in 15) reacting with CEA 
on the surface of tumor cells, radio-immunolocalization of 
CEA-expressing tumors and their metastases has been suc- 
cessful (16-18). Furthermore, model studies in rodents indi- 
cate that anti-CEA monoclonal antibodies may also have a 
future role in tumor therapy (19,20). 
In order to optimize the clinical potential of CEA as a tumor 
marker or for targeting, a better understanding of this mole- 
cule in relation to the already mentioned closely related 
crossreacting antigens is necessary, since CEA represents the 
prototype product of a large gene family. Molecular cloning 
has allowed detailed analysis of this family whose structures 
and expression patterns are complex. These studies have given 
some insight into the possible functions of these molecules. 
We have some indications that other family members may 
also be of clinical interest. The purpose of this review is to 
update what is known on the biology of this gene family and 
report on how this knowledge can lead to improvements in 
the clinical applications of CEA-related molecules. 
SIZE OF THE HUMAN CEA GENE FAMILY 
A number of CEA-related genes, as well as splice variants 
of individual genes, have been identified by molecular clon- 
ing at the cDNA and genomic levels. We have already 
described the history of CEA cloning in an earlier review to 
which we refer for details (1 1). Once the first clones were 
identified, probes became available for isolation and identi- 
fication of other CEA-related genes. On comparing sequences, 
it became obvious that the human CEA gene family can be 
divided into two main subgroups (Table 1). Within a sub- 
group, the different members reveal high sequence conserva- 
tion (80-95% similarity of the N- domain exons at the 
nucleotide level), whereas between subgroups this conserva- 
tion is significantly lower (65-75%). The CEA subgroup 
contains the genes which encode CEA and the classical CEA- 
crossreacting antigens, such as the non-specific crossreacting 
antigen (NCA), which was first described by von Kleist et 
al. (21) and by Mach and Pusztaszeri (22), and the biliary 
glycoprotein 1 (BGPI), first described by Svenberg (23). The 
PSG subgroup contains the genes encoding the pregnancy- 
specific glycoproteins (PSG), which were independently dis- 
covered by Tatarinov and Masyukevich (24) and Bohn (25). 
Bohn named this group of proteins ‘ ‘Schwangerschaftsprotein 
1” (SPl), which has also been used as a tumor marker. 
After the cloning of numerous CEA-related genes in dif- 
ferent laboratories the nomenclature was coordinated at a 
workshop held in Freiburg, Germany, in 1989 (26) and the 
list shown in Table 1 is an update from May 1991. So far, 
maximally 22 different CEA-related genes have been de- 
scribed, with 9 belonging to the CEA subgroup and 13 to the 
PSG subgroup. However, only 1 1  different PSG genes have 
New gene or 
mRNA name Old gene or clone name 
CEA subgroup 
CEA (7 1,167) 
CEA (95,105,106,135) 
CEA (59) 
NCA (7 1,73,74,105,140,14 1 ) 
hsCGM6 (54), M6 (216), NCA-W272 (53) 
BGPI (43). TM-1 CEA (44) 
TM-2 CEA (44) 
TM-3 CEA (44) 
TM-4 CEA (44) 
4-22 (104) 
4-13 (104) 
w211 (94) 
W233 (94) 
W239 (94) 
hsCGM1 (42), 6C3,6A1,7A2, 19H1” 
W264 ( 4 9 ,  CGMla” 
W282 (45) 
CGMlc” 
hsCGM2 (42), 5E8, 7E12” 
W236 (45) 
CGMB“ 
CGM9b 
PSG subgroup 
PSPC (42) 
PSG93 (107), PSPG-D (217), hPSPl1 (75), 
FL-NCA-2 ( 5 5 ) .  hPS3 (218), PSGl, (57) 
PSG16(107) 
PSPG-C (217) 
FL-NCA-1 (56), PSGl, (57), SG9 ( 1  19) 
PSPG-Ci (37), PSG95 (69,219) 
PSPG-D’ (37) 
pSP1-i (220). hc17 (221), PS35 (222), 
hTS 16 (1 18), PSG A (37), SG5 (1 19) 
PSG4 (61), hsCGM4 (42), hHSP2 (75). FL17b 
PSG4 (57), hPS133‘, PSG9 (PS,,) (63,103) 
PSG5 (61), PSPG HL (clone 12-2) (60) 
FL-NCA-3 (55) 
PSpG HL (clone 22) (60) 
hsCGM3 (42). FL26b, PSGGB (69) 
PSG6 (57) 
hPS12(58), PSGlO(103) 
PSG7 (61)a.b.d 
CGM35 (59), PSG8’ 
hTSl ( 1  18) 
PS34 (222), PSPC-Ge, PSPG B (37), PSG7 (223) 
hPS2 ( 5 8 ) ,  hPS91‘ 
11‘ 
18‘ 
PSG14b 
PSPG-E(217), SG8(119) 
CEA 
CEAa 
CEAb 
NCA 
CGMB 
BGPa 
BGPb 
BGPc 
BGPd 
BGPe 
BGPf 
BGPg 
BGPh 
BGPi 
CGM 1 
CGMla 
CGM I b 
CGMlc 
CGM2 
CGM7 
CGMB 
CGM9 
PSG I 
PSG 1 a 
PSG I b 
PSGlc 
PSGld 
PSG 1 e 
PSG 1 f 
PSG2n 
PSG3m 
PSG4 
PSG4a 
PSG5 
PSG5n 
PSG5m 
PSG6 
PSG6r 
PSG6s 
PSG7 
PSG8 
PSG8a 
PSGlls  
PSGllw 
PSG 12 
PSG 13 
PSG14 
PSGl5’ PSG 15 
aUnpublished results. 
’Khan, personal communication. 
Than ,  personal communication. 
dNiemann, personal communication. 
eMansfield, personal communication. 
fHardman, personal communication. 
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been determined so far with some certainty, i.e., through com- 
parison of the N-terminal domain sequences. For PSG 12 and 
PSGl3, this information is lacking as sequence data only exists 
from internal domains for these genes. It cannot be certain 
that they represent separate genes, as they could correspond 
to PSG14 and PSGl5, where only sequence data from the 
N-terminal domains are available. Indeed, an attempt has 
recently been made to characterize all PSG subgroup genes 
and it was concluded that maximally 11 genes exist (S. 
Hammarstrom, personal communication). It is obvious from 
Table 1 that the CEA family is very complex. Not only do a 
large number of genes exist, for which in the majority of cases 
transcripts have been identified, but also splice variants of 
individual genes have been found (e.g., BGP, CGMl , PSGl , 
etc.), which increase the possible number of different pro- 
teins. RNA splice or polyadenylation variants are designated 
by lowercase letters after the gene name, e.g., PSGla, PSGlb, 
etc. In some cases, only minor sequence differences have been 
found, whereby allelic variants of one gene are assumed to 
occur. As will be discussed below, post-translational modifi- 
cations, such as differential glycosylation, increase the vari- 
ability of these proteins even more. For CGMS, PSG15, and 
allelic variants of PSG7 and PSGS, stop codons have been 
found in the N-terminal domain exons and it is assumed that 
they represent either pseudogenes (CGMS, PSG15) or non- 
translatable alleles (PSG7, PSGS). 
SIZE OF THE RODENT CEA GENE FAMILY 
Many investigations regarding the expression patterns of 
CEA-related molecules during fetal development and in nor- 
mal adult tissues, as well as in in vivo functional studies, 
cannot be carried out in humans and necessitate the estab- 
lishment of an animal model system. Rodents, especially mice, 
are an obvious choice for such studies as they are genetically 
well characterized. Introduction of CEA-gene-regulatory 
regions together with indicator genes into transgenic mice, 
or gene inactivation by homologous recombination, can be 
utilized for studying both the regulation of expression and 
function. After transfer of the human CEA gene, with its spe- 
cific regulatory regions to ensure expression in induced colonic 
tumors, the eventual therapeutic effect of anti-human CEA 
monoclonal antibodies can be determined in vivo. 
As a basis for the functional investigations as well as for 
studying the expression patterns during fetal development, 
rodent CEA-related genes first had to be isolated and charac- 
terized. This was achieved in both rat and mouse by using 
probes from human CEA gene family members (27-32). Other 
workers successfully isolated CEA-related genes (33), or pro- 
teins (34,35), after first studying specific functions. The impli- 
cations of these functions will be discussed in more detail 
below. Rodent CEA-related genes can also be divided into 
subgroups based on sequence comparisons. The present sit- 
uation is shown in Table 2 which shows three subgroups. 
TABLE 2. Classification of the Rodent CEA Gene Families 
New gene or 
mRNA name Old gene or clone name 
Subgroup I 
Mouse 
mCEAl(29),mmCGMl(28) mmCGM 1 
mCEA2 (29), mmCGM2 (31) mmCGM2 
mCEA3 (29) mmCGM3 
mCEA4 (29) mmCGM4 
ecto-ATPase (33), pp 120/HA4 (152), 
Rat 
C-CAM 105 (124) ecto-ATPase 
Subgroup 2 
Mouse 
mmCGM5 (32) mmCGM5 
mmCGM6 (32) mmCGM6 
mmCGM7 (32) mmCGM7 
mmCGM9 (32) mmCGM9 
mCGMl (27,30) mCGMI 
mCGM3 (27) mCGM3 
mCGM4 (27) m CGM4 
Rat 
Subgroup 3 
Mouse 
Rat 
mmCGM8 (32) mmCGM8 
mCGM2 (27) mCGM2 
Within a subgroup, the genes reveal 80-90% sequence simi- 
larity at the nucleotide level, whereas between subgroups the 
similarity drops to 55-60%. To date, maximally 12 rodent 
CEA-related genes have been described although some of these 
may represent splice variants of the same gene, e.g., mmCGM2 
and mmCGM4 (Table 2 and 29). 
If we compare sequences between the rodent and human 
CEA gene family members, it is impossible to determine indi- 
vidual counterparts. We find 50-60% sequence similarity, im-  
spective of the subgroups. A rapid sequence divergence of 
the CEA gene families is obvious between these two mam- 
malian orders, and detailed, computer-assisted analyses indi- 
cate a parallel but independent evolution, which took place 
after mammalian divergence (36,37). This complicates the 
application of an animal model, but expression patterns help 
to assign at least the subgroups. 
DOMAIN STRUCTURE IDENTIFIES CEA-RELATED 
MOLECULES AS MEMBERS OF THE 
IMMUNOGLOBULIN SUPERFAMILY 
Analysis of the deduced primary and secondary structures 
of the human and rodent CEA-related molecules have made 
it possible to define specific domains, which are common to 
the respective CEA gene families. However, differences in 
the domain combinations are found, especially for members 
of the second rodent subgroup (Table 2), compared to all human 
CEA-related molecules. 
As can be seen in Figures 1 and 2, all CEA-related mole- 
CEA Subgroup 
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CEA 
UCA 
CQM 6 
BOP a 
BQP c 
BOP b 
BQP d 
CQM 14 
CGM 7 
B 3  M 
la Q M 82 W 92 M z m  
L N A 1  B1 A 2  B 2  A 3  .............. ...................... :.:.:.;;: .......... ............... . . .. . . . . .. ...... c c I c c I c c I c c I c c I c c ................... 
L N  A B M  
....................................... 
.......................... m::,.,: ............................ :::   . ...... c c I c c a 
Y ia &z M s y 2 s  
L N A 1  8 1  L N  A 1  B1 A 2  C 
L N  A 1  8 1  TM cyt 
34 K M U 6  
L N TM Cbt L N A' 
EGP I 
34 100 K M 31 
L N TM Cvl 
L N A 1  B 1  C 
34 100 39 16 46 
PSG Subgroup 
PSG l b  
PSG l a  
PSG 4. 
PSG 8. 
PSG l d  
PSG 3 
PSG 11s 
PSG 1c 
PSQ Br 
PSG 2 
PSG 11w 
PSG If 
PSG6 
L ti A 1  8 2  c 
f c c l c c a  
a4 110 U w law 
L N A 2  8 2  C 
34 110 B2 m 493 
V A  1 C C I C C p J  
L N TM cyt 
34 im 39 31 
Fig. 1. Domain stIuctures of human CEA-related proteins, based on deduced 
amino acid sequences. The proteins are listed in the two subgroups. (For 
original literature see Table 1 .) Proteins encoded by splice variants of indi- 
vidual genes are differentiated by lowercase letters after the gene name. Dif- 
ferent domains are indicated by letters above the blocks and different shading, 
whereby homologous regions have the same shading. L = leader peptide, 
N = N-terminal (IgV-like) domain, A1-A3 andBI-B3 = IgC-likedomains, 
M = hydrophobic domain replaced by glycosyl phosphatidyl-inositol anchor, 
C = C-terminal domain, TM = transmembrane domain, Cyt = cytoplas- 
mic domain. Apart from the leader peptide, the domain borders are based 
on exon structures and do not necessarily correlate with functional regions 
(e.g., TM and Cyt domains). Amino acid numbers are presented below the 
blocks. The variability in length of the NCA and CCM6 M domains and the 
PSG C-terminal domains are listed. The positions of cysteines are indicated 
in the blocks (C). 
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Subgroup 1 
L N  A 1  0 1  A 2  TM Cyt 
I 
mm CGMl . 
34 108 84 92 40 4 
.m . mm CGM2 
34 108 82 40 4 
Subgroup 2 
L N 1  L'2 N 2  L'3 N 3  L'4 N 4  C5 N 5  A 
rn CGMl 
34 108 12 108 12 108 10 108 8 108 83 
L N 1 L'2 N 2 L'3 N 3 A 
mm CGMS 
mm CGMQ 
93 34 10% 12 lea 12 108 
Fig. 2. Domain structures of the rodent CEA family based on deduced amino acid sequences. The proteins 
are listed according to their subgroups. (For original literature see Table 2 . )  Shading and labelling as for Figure 1. 
cules have a leader (L) domain or signal peptide of 34 amino 
acids. This is necessary to direct the nascent proteins through 
the rough endoplasmic reticulum membrane for passage to 
the plasma membrane, where they either become anchored, 
as found for most of the human CEA subgroup and rodent 
subgroup 1 molecules, or they are secreted, as found for most 
members of the human PSG subgroup and rodent subgroup 
2. This leader peptide is cleaved off and is absent in the mature 
proteins. The main backbone of all CEA-related molecules 
is made up of a variable number of immunoglobulin-like 
domains, which places the CEA gene family within the immu- 
noglobulin supergene family (38,39). The human CEA-related 
molecules always contain one N-terminal domain (N domain) 
of 108-1 10 amino acid residues, whose derived secondary 
structure reveals homology to the immunoglobulin variable 
(IgV) domains. This is then followed by a different number 
of immunoglobulin constant-like (IgC) domains, consisting 
of 92 and 96 (A domains) or 86 amino acids (B domains). 
Each IgC-like domain contains at least two cysteine residues, 
which are assumed to stabilize the immunoglobulin-like fold 
via a disulphide bridge (40). Despite the absence of cysteine 
residues in the N-terminal domains a similar fold is predicted, 
which could be stabilized by interactions between hydropho- 
bic amino acids at the expected cysteine sites, as well as by a 
conserved salt bridge (39,41,42). The number of IgC-like 
domains in human CEA-related molecules varies from none 
in CGMla,c and CGM7 through two (e.g., NCA) or three 
(e.g., PSGl),  to six in CEA (Fig. 1). Along with post- 
translational modifications, such as differential glycosylation, 
this variability in the domain number accounts for the large 
size differences found for the protein products (cf. Tables 1 
and 3; 11). 
As seen in Figure 2 the domain organization for members 
of the rodent subgroup 1, i.e., for mmCGMl(29), mmCGM2 
(31), and the rat ecto-ATPase (33), is similar to splice vari- 
ants of BGP (43,44), which belongs to the human CEA sub- 
group (Fig. 1). However, the members of the second rodent 
subgroup, i.e., rnCGMl (30), mmCGM5, and mmCGM9 
(32) show a very different combination of immunoglobulin- 
like domains compared to human CEA family members. In 
this case, three (mmCGM5, mmCGM9) and five (rnCGM1) 
IgV-like N domains, of similar lengths to their human coun- 
terparts, are followed by a single IgC-like A domain (Fig. 2). 
Due to the exon structure, which will be discussed below, 
the internal N domains are separated by sequences normally 
found in the leader (L) domains. This very different combi- 
nation of immunoglobulin-like domains makes it impossible 
to identify the corresponding human subgroup based on struc- 
tural studies alone, 
Most members of the human CEA subgroup as well as those 
belonging to the first rodent subgroup are apparently mem- 
brane-bound. In some cases, their derived amino acid 
sequences indicate that they are integral membrane proteins, 
i.e., BGPa,b,c, and d (43,44), CGMla and c (45 and results 
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TABLE 3. Assignment of CEA-Related Genes to Known Antigens: Current Status 
Gene Antigen M, ( X 1,000) deglyc. predicted" anchorage Methods applied for assignment Evaluation 
M, ( X 1000) M, unglyc. Membrane 
CEA 
NCA 
BGP 
CGM6 
? 
? 
? 
? 
? 
? 
? 
? 
CEA- 180 (3) 
NFA l(170) 
160 kDa antigen (225) 
MA-100 (227) 
NCA-50 (21) 
(NCA-2) (226) 
NCA-90 (228) 
TEX (1 10) 
BGPI (229) 
NCA-95 ( 1  15) 
CEA-160 (230) 
NCA-26 (232) 
NCA-58 (233) 
NCA-80 (233) 
NCA-95 (232) 
NCA-90 (232) 
NCA-140 (234) 
NCA-160 (228, 232) 
180 
20-30 
I65 
100 
45-60 
90 
75 
90 
95 
I60 
26 
58 
80 
90 
95 
140 
160 
7gb (224) 
? 
? 
? 
35' (50,110) 
35'(51) 
35' (1 10) 
? 
42' (50) 
64'(231) 
14d (45) 
4Ib (233) 
69b (233) 
2gd (232) 
45d (232) 
70d (234) 
90" (228) 
72.3 
- 
- 
- 
33.9 
33.9 
33.9 
Different 
splice 
variants 
33.9 
GPI (38,46,49) 
? 
? 
? 
GPI (50,52,110) 
GPI (51) 
GPI (1 10) 
Presumably trans- 
membrane (17) or 
secreted (see Fig. I )  
GPI (54) 
? 
Membrane, not PI- 
PLC sensitive (232) 
Secretory (233) 
Secretory (233) 
GPI (232) 
GPI (232) 
Membrane, not PI- 
PLC sensitive (234) 
Membrane, not P1- 
PLC sensitive (2321 
Amino acid sequences (38) 
Amino acid sequence (170) 
Amino acid sequence (225) 
Amino acid sequence (225) 
Amino acid sequences, expression 
of cDNA and immunological 
assignment by mAb (50,110) 
N-terminal amino acid sequence, 
M, after deglycosylation, 
peptide map (5  1 ) 
Amino acid sequences ( 1  10) 
Amino acid sequences (43) 
Expression of cDNA and 
immunological assignment with 
mAbs, tissue distribution (54) 
Confirmed 
Probable 
Probable 
Probable 
Confirmed 
Probable 
Confirmed 
Confirmed 
Probable 
aDependent on the deglycosylation method different M, can be predicted. 
bDetermined after tunicamycin treatment, no N-linked carbohydrates, GP1-moiety present. 
'Trifluoromethansulfonic acid treatment, terminal Asp-linked GlcNAc present, GPI-moiety partially removed. 
dEndoglycosidase F treatment, M, determined as in '. 
to be published), CGM7 (49 ,  mmCGMl and 2 (29,31), and 
rat ecto-ATPase (33). In these proteins, a hydrophobic trans- 
membrane (TM) domain is predicted to follow the last 
immunoglobulin-like domain, and this in turn is succeeded 
by a cytoplasmic domain (Cyt), whose length can vary (Figs. 
1, 2). Alternatively, some human CEA-subgroup members 
have been shown to be anchored after post-translational mod- 
ification and replacement of the hydrophobic membrane (M) 
domain (Fig. l) ,  with a glycosyl phosphatidylinositol moi- 
ety, e.g., CEA (46-49), NCA (50-52), and the presumed prod- 
uct of the CGM6 gene, NCA-95 (53,54). Four members of 
the CEA subgroup (CGMlb, BGPg,h,i) apparently repre- 
sent secreted proteins, as they lack a hydrophobic C-terminal 
domain. However, corresponding proteins must first be iden- 
tified before this can be confirmed. 
The majority of the human PSG subgroup members have 
very short, mainly hydrophilic, C-terminal domains consist- 
ing of two to 21 amino acids and the rodent subgroup 2 mem- 
bers (rnCGM1, mmCGM5, mmCGM9) completely lack C 
domains. This indicates that these proteins are directly secreted 
from the cells and, indeed, in experiments where human PSG 
cDNA clones have been transfected into eukaryotic cells, the 
products appear quickly in the supernatant (55-57). One pos- 
sible exception has been described by Zheng et al. (58) for 
PSGl l w  (Fig. l) ,  which was isolated from a placental cDNA 
library. This cDNA species apparently encodes a PSG pro- 
tein with a long hydrophobic C-terminal region of 80 amino 
acids, which could well be used for membrane anchorage. 
Alternatively, this clone may merely represent an incompletely 
spliced mRNA product, because on comparison with PSG 
genomic sequences (59-61), it is clear that the intron follow- 
ing the B2 exon is still present in this particular cDNA clone 
and that the hydrophobic C-region is encoded by these intron 
sequences. Polyadenylation was, however, found in this clone, 
but unequivocal proof that it encodes a membrane-bound PSG 
can only come through identification of the corresponding 
protein, e.g., in the placenta. 
CHROMOSOMAL LOCALIZATION OF THE HUMAN 
AND MOUSE CEA GENE FAMILIES 
Two different approaches have allowed the chromosomal 
localization of the human CEA gene family. One approach 
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utilized humadrodent hybrid cell analyses (62-64), whereas 
the second approach was to hybridize human metaphase chro- 
mosome spreads with tritium-labelled DNA probes (61,65- 
68). These experiments have shown that the CEA and PSG 
subgroup genes are clustered on the long arm of chromosome 
19 in theregion 19q13.1-19q13.3. Usingsomaticcell hybrids, 
Schonk et al. (64) reported that the CEA gene family is located 
on the distal portion of 19q13.1, close to the genes encoding 
hormone-sensitive lipase (LIPE), transforming growth factor 
(TGF)-P 1, and cytochrome P450 subfamily IIA (CYP2A). In 
one report we provided evidence that CEA-related genes may 
also be located on the short arm (19~13.2-19~13.3) of chro- 
mosome 19 (65). However, the hybridization signal seen was 
only found by using a genomic probe containing the A and 
the start of the B domain exons from the NCA gene, includ- 
ing intron sequences. As a corresponding signal was not vis- 
ible using a CEA cDNA fragment containing A and B 
domains, we assume that this was probably due to cross- 
hybridization with intron sequences and that all CEA-related 
genes are indeed located on the long arm of chromosome 19. 
We have analysed this region more closely by using pulse- 
field gel electrophoresis in order to separate large DNA frag- 
ments resulting from digestion with rare-cutting restriction 
endonucleases. After transfer to charged nylon membranes, 
the digested DNA was hybridized with gene-specific probes 
in an attempt to determine putative linkage of CEA-related 
genes. Together with single and double digestions, it was pos- 
sible to construct a long-range restriction map of this region. 
With the help of chromosome walking studies, fine restric- 
tion endonuclease mapping has also been carried out for some 
regions. These results have been confirmed by H. Mohren- 
weiser and collaborators at the Lawrence Livermore National 
Laboratory, USA. This group has constructed a cosmid library 
from chromosome 19 and with the help of fingerprinting, over- 
lap detection algorithms, and chromosome walking, they have 
been able to identify a large number of overlapping cosmid 
clones from the CEA gene family region through hybridiza- 
tion with a conserved sequence from a CEA cDNA clone. In 
parallel, the same group has carried out high-resolution in 
situ mapping by using gene-specific probes on interphase chro- 
mosomes. These and our results indicate that the whole CEA 
gene family apparently extends over a 1.2 Mb region at 
cen 
CGM7 CGM2 CEA NCA CGMl 
19q 13.1. Where determined, individual genes are very closely 
linked, being separated by 16 kb (CEA subgroup genes; to 
be published), or 6 kb (PSG genes; 61,69). The PSG genes 
have been mapped telomeric of the CEA subgroup by analy- 
sis of somatic cell hybrids (T. Willcocks, personal commu- 
nication). A schematic map of the CEA gene family region, 
including the gene order and orientation as far as it is known, 
is shown in Figure 3. 
Using a probe from a mouse CEA-related gene (mmCGM8) 
belonging to rodent subgroup 3 (Table 2) to analyse a panel 
of interspecific backcross mice, this gene has been located at 
mouse chromosome 7 (A. Saunders and M. F. Seldin, per- 
sonal communication). This region is syntenic to human chro- 
mosome 19; i.e., the counterparts of a number of genes located 
at human chromosome 19 are found to be similarly linked on 
mouse chromosome 7 (70). 
GENOMIC ORGANIZATION OF 
CEA-RELATED GENES 
Analysis of the genes encoding CEA and related molecules 
in humans (42,59-61,69,71-74) and in rodents (27,30,32) 
has revealed a close correlation between the domains and the 
exon regions. This is shown in Figure 4 for the CEA gene. 
Such a correlation is also a typical feature for other members 
of the immunoglobulin supergene family (40). A closer anal- 
ysis of the derived amino acid sequences in the CEA gene 
shows that the immunoglobulin-like domains, which contain 
highly ordered P-sheets, are always surrounded by proline- 
rich regions located close to the exon borders (71). These 
regions disrupt ordered structures, thus marking the bound- 
aries between adjacent domains. 
In rodents and humans, the first exon encodes the 5'-un- 
translated region and the first two-thirds of the leader pep- 
tide. The second exon encodes the rest of the leader and the 
complete N-terminal domain. In rodent subgroup 2 (Table 
2), this exon is repeated up to five times, as found in rnCGMl 
(30 and Fig. 2). Following the N-terminal domain exon is a 
variable number of IgC-like (A and B) domain exons, rang- 
ing from one in mmCGM5 (32) to six in CEA (Fig. 4). Beyond 
these exons, variability is found in the number and structure 
of the exons encoding the M, TM, and Cyt or C-terminal 
qter 
BOP CGMB CGM8 PSO gene duster 
approx. 1.2 Mb 
Fig. 3. Schematic map of the CEA gene family region on the long arm of chromosome 19. The genes are 
shown as filled-in (CEA subgroup) or an open (PSG subgroup) block. The direction of transcription is indicated 
by arrows. cen = centromere, qter = telomeric end of chromosomal long arm. 
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Fig. 4. Correlation of exon and domain structures for the CEA gene. The genomic structure of the CEA gene is 
shown in the upper part of the figure as published elsewhere (71), and the lower part of the figure shows the 
domain structure (cf. Fig. I) .  The exon names are the same as the domains, or are discussed in the text. 
domains and the 3'-untranslated regions (cf. Fig. 1). A 
detailed analysis of the organization and the many splice vari- 
ants found for the human CEA gene family in this 3'-region 
was recently reported by Zimmermann et al. (57) and will 
not be further discussed here. It is of interest to note that the 
otherwise highly similar PSG subgroup genes show variabil- 
ity in this region. Indeed, this variability can be used to iden- 
tify various classes within the human PSG subgroup, whereby 
proteins with similar C-terminal domains can be classified 
together (Fig. 5) .  So far, little is known about the genomic 
organization of the C-terminal and 3'-untranslated regions 
of the rodent CEA gene family. 
Not all of the putative exons found through human geno- 
mic analyses are present in corresponding cDNA clones. For 
example, the genes encoding PSG4 and PSGS (60,61) both 
have four internal exons, each of which contains an IgC-like 
(A 1, B 1, A2, B2) domain, cDNA clones have been charac- 
terized for the PSG4 gene, which lack the B1 domain (57,75), 
and PSGS cDNA clones have been described which lack both 
the A1 and B1 domains (55,60). The splice sites for the miss- 
ing exons do not appear to be mutated when compared to 
splice consensus sequences (76), but in both genes it is inter- 
esting to note that the B1 exons contain a stop codon (60,61). 
The A1 exon in the PSGS gene, on the other hand, contains 
an open reading frame, so that potentially, protein products 
including this domain could also exist. A similar situation 
for exon deletion was described by Oikawa et al. in PSG8 
(59, Table l ) ,  where a mutated donor splice site for the B1 
exon was found. It is interesting that no PSG cDNA clone so 
far analysed has been shown to contain a B1 exon (Fig. I), 
although the reasons for this are unknown. 
Exon deletion has also been found for members of the CEA 
subgroup; e.g., differential splice variants have been described 
for BGP (44, see Fig. 1). The A1 exon of CGMl apparently 
contains a stop codon, which would lead to premature termi- 
nation of translation from transcripts containing this domain, 
e.g., CGMlb (Fig. 1). Interestingly, two other splice vari- 
ants (CGMla,c) do not contain this exon, whereby read- 
through can be achieved (45). One of the criteria used to 
distinguish the CEA and NCA transcripts has been through 
Subclass 1 
PSGla DWTVP PSGlb EAL PSGlC AYSSSINYTSGNRN PSGld GKWIPASLAIGF 
PSG4a . .IL. PSG4b --- PSG4C 
PSG7a . .SL. PSG7b .s. PSG7c ... G........D. P8G7d ............ 
PSG8a .. .L. PSGBb ... PSGBC ......... AVY PSGBd .. R..V.....I 
------------ PSG4d -------------- 
Subclass 2 
PSG2 
PSG3 
PSG5 
Subclass 3 
PBQ6r 
ASTRIGLLPLLNPT 
.PSGT.H..G...L 
.PSG..R......I 
ETABPQVTYAGPNTWFQEILLL PSG68 GPCHGNQTESH 
PSG11S ..... DL...ES 
Fig. 5. Subgroups of the human PSG family based on sequence similarity of their deduced C-terminal domains 
(cf. Fig. 1). Amino acid sequences are shown in the single-letter code, whereby homologous regions are grouped 
together. Dots indicate identical amino acids and dashes unknown sequences in comparison with the first-listed 
C-terminal domain in each subclass. For PSG4, splice variants 4b, 4c, and 4d have not yet been found, but are 
predicted. The original literature is listed in Table 1. 
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hybridization of probes from their 3’-untranslated regions (65), 
where they differ completely. However, analysis of the CEA 
gene (71) reveals that this is due to differential splicing and 
that a putative exon with an NCA-like 3’-untranslated region 
also exists, with an apparently intact splice acceptor site. 
Although no CEA transcript with an NCA-like 3’-untranslated 
region has been described so far, its existence cannot be ruled 
out. Furthermore, it may be expected that similar sets of 
3’-untranslated region exons might also exist in other CEA- 
related genes. 
It is interesting to note the presence of Alu-like repetitive 
elements in the homologous 3’-untranslated regions of the 
CGM6 and CEA mRNAs (5339).  About 300,000 Alu- 
elements are present in the human genome, mainly in introns 
and intergenic regions (77). In the mature CEA mRNA two 
Alu sequences are found and in CGM6 mRNA one is pres- 
ent. As the Alu elements are located at different sites in the 
two mRNAs, independent insertion of these mobile elements 
must have occurred after separation of the two genes during 
evolution. Using the polymerase chain reaction (PCR), we 
could detect the presence of the first Alu-element in the CEA 
mRNAs of two primates, i.e., chimpanzee and African green 
monkey, suggesting the insertion of this element before pri- 
mate speciation. At the genomic level, at least six Alu-elements 
have been found in a 7.5 kb section of the 3’-untranslated 
region of the CEA gene, which is an exceptionally high con- 
centration, although the relevance is still unknown (71,72). 
Other interesting repetitive elements composed of simple 
DNA sequences have also been found in various non-coding 
regions of CEA-related genes. For example, a poly(dC-dA) 
sequence of varying length has been found in the first intron 
of all human CEA-related genes (42,72-74). In the PSG sub- 
group this is followed by a poly(dG-dT) sequence and in rat 
group 2 genes homopurine/homopyrimidine stretches with 
d(CCTT) and d(GGA) units are found at similar positions (27). 
More recently, we have found similar repetitive simple 
sequences located approximately 180 nucleotides upstream 
of the transcriptional initiation sites of two human PSG genes 
and the CGM6 gene (A.-M. Eades-Perner, personal commu- 
nication). The relevance of these simple sequences remains 
to be determined, although it is known that they can form 
Z-DNA (78). Such sequences may play a role in the regula- 
tion of gene expression and, indeed, correlate with DNase I 
hypersensitive sites in the 5’-region of the human P-like-globin 
gene domain, where they are located close to a number of 
enhancer elements (79). They have been shown to be impor- 
tant for regulating expression of the P-globin gene (80). In 
the rat growth hormone gene promoter region, repetitive sim- 
ple sequences exist which could also play a role in regulat- 
ing gene expression there (81). It is thought that these 
elements, in their open conformation, may allow easy access 
for factors involved in control of transcription. Alternatively, 
simple sequences could play a role in recombination events 
(82,83), or gene rearrangement (84). 
EXPRESSION PAmERNS OF CEARELATED GENES 
IN HUMANS 
Before the in vivo function of CEA-related molecules can 
be properly investigated, it is important to determine where 
the individual molecules are expressed. The CEA family shows 
great variability in the expression patterns of individual mem- 
bers, as defined by immunological methods (1 1). NCA reveals 
a broader expression spectrum than CEA and is found not 
only in tumors but also in a variety of normal fetal and adult 
tissues such as colonic mucosa, lung, spleen, liver, etc., as 
well as in polymorphonuclear granulocytes, macrophages, and 
monocytes (85,86). BGP1, on the other hand, was discov- 
ered in the epithelium of bile canaliculi (23). PSG are 
expressed in increasing amounts by the placenta during preg- 
nancy, from which they are secreted into the maternal blood- 
stream. At term they represent the major placental protein, 
with concentrations of up to 400 p.g/ml serum (87). One major 
drawback of the immunological approach for determination 
of expression is that it is difficult to determine the specificity 
of the antibodies used, as cross-reactivity can only be ruled 
out when all the antigens have been isotated and fully char- 
acterized. Another problem is that the identification of a given 
antigen in a specific tissue or organ does not necessarily mean 
that this molecule is actually produced there. For example, 
these molecules could be secondarily bound or engulfed by 
phago- or pinocytosis, e.g., as found for Kupffer cells in the 
liver, where a receptor-mediated endocytosis of CEA has been 
reported (88,89). 
With the help of molecular cloning of CEA-related cDNAs 
into expression vectors, followed by subsequent transfection 
into eukaryotic cells, the specificity of polyclonal and 
monoclonal antibodies can be determined against individual 
products. Stable transfectant clones already exist which express 
CEA (52,90,91, and to be published), NCA-50/90 (51,52, 
90,92), NCA-95 (54,45), BGPa and b (93,94), CGMla (G. 
Nagel, personal communication), PSGla (55,57), PSGld and 
PSG5n (55 ) ,  and PSG3 and PSG6r (to be published). This 
panel of transfectants is continuously being expanded; how- 
ever, even a complete panel cannot ensure that all naturally 
occurring epitopes will be contained therein. For example, 
differential glycosylation and proteolysis, as found in vivo, 
give rise to additional products, whereby modified or new 
epitopes could be generated. 
Through the specific determination of mRNA species 
encoded by an individual gene, the problem encountered by 
immunochemical investigations at the protein level can be 
circumvented. Sequence comparisons of all known CEA- 
related genes make it easier to design specific DNA or RNA 
probes for differentiation of individual mRNAs than to develop 
specific antibodies against corresponding proteins. Various 
methods are available for identification of these mRNA spe- 
cies. One approach is to extract RNA from different organs, 
followed by electrophoretic size fractionation, transfer to nylon 
membranes, and hybridization with gene-specific radiolabelled 
DNA probes (Northern analysis). Alternatively, mRNA can 
be converted to DNA and amplified by using gene-specific 
oligonucleotides in PCR, which has the advantage of sim- 
plicity and high sensitivity. A third possibility is to cany 
out in situ hybridization on tissue sections, whereby the 
actual cells expressing individual CEA-related transcripts 
can be identified. 
Many studies to determine expression of CEA-related genes 
at the transcriptional level have applied the Northern blot tech- 
nique( 10,44,54,57,58,61,65,95-107). Using this approach, 
and with the help of gene-specific or subgroup-specific DNA 
probes, a number of mRNA species varying in size have been 
identified in different tumors and some normal tissues. For 
some genes, more than one transcript exists, representing either 
mRNA species with different polyadenylation sites (e.g., 
CEAa,b, BGPe,f, PSGld,e) or splice variants of individual 
genes (e.g., BGPa-i, PSGla-d), as found by cDNA cloning. 
In some cases, different genes or splice variants of the same 
genes encode transcripts of similar sizes (e.g., PSGla and 
PSG4a), which makes it difficult to identify CEA-related 
mRNA species by size alone. Furthermore, for the highly 
conserved PSG subgroup (Table I ) ,  it is only possible to 
differentiate individual transcripts by using oligonucleotide 
probes, which have limited sensitivity in Northern blot analy- 
ses. Therefore, this method cannot be used to screen for low- 
copy-number mRNAs. 
An alternative approach with much higher sensitivity is 
PCR. Once sequences for individual genes or their mRNAs 
and splice variants are available, specific oligonucleotide prim- 
ers can be synthesized for conversion of putative transcripts 
into cDNA and subsequent amplification of DNA fragments. 
This approach has a number of benefits over the Northern 
technique, due to its high sensitivity. This allows investiga- 
tions on biopsy material to be carried out, which normally 
would not provide enough RNA for Northern blot hybridiza- 
tion. We have established a PCR assay system for differentia- 
tion of CEA, NCA, CGM6, BGP, and PSG subgroup 
transcripts. The specificity of each set of of primers has been 
tested against individual cDNA clones and we are currently 
analysing large numbers of tumors and normal tissues for tran- 
scripts of the different genes. We are now able to determine 
the mRNAs of individual genes with 500 x less total RNA 
than with conventional Northern blot analyses. Furthermore, 
in some tissues, where we gained negative results with the 
latter method, PCR has unequivocally identified transcripts 
for some CEA-related genes. 
Both Northern blot and PCR analyses only allow determi- 
nation of transcripts in tissue extracts, but do not allow dis- 
crimination of the individual active cells. This type of analysis 
can best be carried out by in situ hybridization on tissue sec- 
tions. This method has already been adopted to determine 
which cells transcribe the CEA and NCA genes in cell cul- 
ture as well as in a number of colorectal adenomas and carci- 
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nomas (98). The authors report positivity in 7/15 adenomas 
and 13/15 adenocarcinomas with the CEA probe. With the 
NCA probe, 6/ 15 adenomas and 10/ 15 adenocarcinomas were 
positive. The intensity of the signal appeared to be stronger 
in adenocarcinomas than in adenomas. In general, NCA and 
CEA transcripts were coexpressed and showed a very similar 
localization in positive cells. In a comparison with Northern 
blot analyses it was found that the in situ applied method was 
less sensitive and in some of the tissues which were appar- 
ently negative, Northern blot studies identified both CEA 
and NCA transcripts. Similar results were reported by Monde 
et al. (108). 
Taking all these analyses together, distinct expression pat- 
terns are becoming apparent for individual CEA-related 
mRNAs. In general, NCA and CEA appear to be coexpressed 
in a variety of adenocarcinomas or derived cell lines and ade- 
nomas (10,65,97,101,l05>. Although the CEA levels are 
much lower in corresponding normal tissues, e.g., in normal 
colonic mucosa as compared to colorectal adenocarcinomas, 
CEA transcripts are found in comparably high amounts (100). 
In contrast, the steady-state levels of NCA transcripts are nor- 
mally very low in normal intestine compared to much higher 
levels in colonic carcinomas, as reported by a number of groups 
(10,97,101,109). In parallel, we havealso found higherNCA 
antigen levels in the sera of colonic tumor patients. These 
results indicate that NCA may also be a useful marker for 
colonic tumors. 
NCA transcripts, but not CEA transcripts, have been found 
at very low levels in peripheral leukocyte preparations (45) 
and at much higher levels in bone marrow extracts or leuko- 
cytes from chronic myeloid leukemia (CML) patients. Tran- 
scripts from the CGM6 gene have also been discovered in 
these leukocyte preparations, but nowhere else to date (54). 
For the NCA and CGM6 genes, the corresponding antigens 
are NCA-50190 or TEX (50,5 1,110) and probably NCA-95 
(54), respectively. We have found these antigens mainly in 
neutrophilic, to a lower extent in eosinophilic, but not in baso- 
philic granulocytes, and judging by the steady-state levels of 
their transcripts, the genes are apparently active in immature 
but inactive in mature granulocytes (54). Therefore, these 
mRNAs may be useful as markers for granulocyte differenti- 
ation. Recently, through investigations using monoclonal anti- 
bodies, some members of the CEA gene family or epitopes 
thereof have been correlated with surface markers from the 
CD series. Watt et al. (1 11) have recently shown that the 
neutrophil-specific cluster of differentiation, CD66 (1 12,113), 
is present on members of the CEA family, and CD67 repre- 
sents a cluster which probably corresponds to NCA-95 (1 14 
and to be published). Immunological studies have revealed 
the presence of NCA-95 in macrophages and monocytes (1 15). 
Corresponding transcripts have, however, so far not been found 
in these cells (1 16), indicating that NCA-95 is phagocytosed, 
but not expressed there. In support of this are recent data from 
Novak-Hofer et  al. (1 17), who investigated the binding activ- 
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ities of monoclonal antibody 47 (1 15), which recognizes 
NCA-95 on a promyelocytic cell line (HL-60). Dimethyl- 
sulfoxide (DMSO) induces these cells to differentiate into neu- 
trophils, whereby the Mab 47 binding increased up to fourfold 
7 days after treatment. In contrast, phorbol- 12-myristate- 
13-acetate (PMA), which induces differentiation of HL-60 
cells into monocyte/macrophages, led to a decrease in bind- 
ing. These results suggest that NCA-95 is expressed at a low 
level in promyelocytes and is up-regulated during neutrophilic, 
but is switched off during monocytic, differentiation. 
PSG transcripts have mainly been found in placenta, where 
they are apparently coexpressed (61,102). PSG cDNA clones 
have also been found in libraries from a number of other tis- 
sues, such as testis (118), fetal liver (55-57), salivary gland 
( 1  19), HeLa cells ( 7 3 ,  two myeloid cell lines-HL60 (60) 
and KG1 (103)-and the spleen of a CML patient (G. Nagel, 
personal communication). These results indicate that PSG are 
not, as the name would suggest, pregnancy specific, but it 
remains to be determined whether PSG proteins have a func- 
tion in these tissues. In most of the above-mentioned stud- 
ies, the existence of PSG is based solely on the isolation of 
cDNA clones from the RNAs of different tissues. However, 
this yields no information on the absolute amounts of the cor- 
responding PSG mRNAs, which in extreme cases, may only 
be present as single copies in the RNA preparations. At the 
protein level, PSG are synthesized by placental and normal 
fibroblast cell lines (120,121). In some instances, differen- 
tial expression of individual PSG species has been reported, 
e.g., PSG6 transcripts are either absent or not very prevalent 
in normal placenta (61,69), whereas their concentration in 
hydatidiform mole, a benign tumor of trophoblastic origin, 
is very high (69). Similarly, variability in the mRNA steady- 
state levels of other PSG genes may relate to pathological 
pregnancies (102). 
Taken together, the RNA analyses (not including identifi- 
cation of cDNA clones) indicate a relatively narrow range of 
expression for individual members of the human CEA gene 
family, although more determinations remain to be carried 
out before distinct patterns can be defined. 
IDENTIFICATION OF HUMANRODENT 
COUNTERPARTS BY COMPARING EXPRESSION 
PATTERNS 
Expression patterns have been compared in an attempt to 
identify rodent counterparts to human CEA-related genes. 
Although anti-human CEA (28) and PSG antisera (1 22) were 
shown to cross-react with CEA/PSG-related antigens in 
rodents, a specific assignment of counterparts could not be 
made due to the lack of specificity of the antisera for indi- 
vidual molecules. Investigations have also been carried out 
at the transcriptional level by using Northern blot analyses 
(27,28,30) and in situ hybridization studies (123). 
Transcripts encoded by members of the rodent CEA gene 
family subgroup I (Table 2) have been identified by cDNA 
cloning as present in mouse colon (28,31). Utilizing probes 
from mmCGMl and mmCGM2 for Northern blot analyses 
under low-stringency conditions, transcripts of different sizes 
have been identified in mouse colon, liver, and uterus (28,3 l), 
an expression pattern which is similar to that for the human 
CEA subgroup. Huang et al. (123) have made detailed expres- 
sion studies in developing mouse embryos with the same 
probes. Northern blot studies allowed identification of tran- 
scripts in fetal colonic and intestinal tissues, while in situ 
hybridization investigations carried out at low stringency also 
revealed expression of rodent CEA-related genes in cartilage 
and bone, meninges, muscle layers of the stomach and intes- 
tine, blood vessel walls, bronchioles, and dermis at various 
stages of mouse embryonic development. These tissues are 
all derived from mesenchyme and the authors speculate that 
CEA-related molecules may play an important role during 
active morphogenesis. The implications of these findings 
regarding function will be discussed in more detail below, 
but the benefits of an animal model for such studies are obvious. 
The expression pattern of rodent subgroup 2 (Table 2) has 
also been investigated at the transcriptional level. Northern 
blot analyses using gene-specific probes from rnCGM 1 under 
high-stringency conditions have revealed mCGM 1 transcripts 
only in rat placenta, but not in other tissues or organs (27,30, 
and to be published). We have similar results for expression 
of mmCGM.5 in mouse placenta (32). These results have been 
confirmed by in situ hybridization investigations, whereby we 
have been able to localize rnCGMl transcripts to the spon- 
giotrophoblast and some giant trophoblast cells. In addition, 
we find some labelling in the connective tissue surrounding 
the ducts of adult salivary glands, which correlates with the 
presence of PSG transcripts in human salivary glands (1 19). 
Taken together, these data strongly indicate that the rodent 
subgroup 2 genes (Table 2) encode the PSG counterparrts. 
Antibodies raised against rodent CEA-related proteins have 
been used for the localization of these molecules. Recently, 
Aurivillius et al. (124) showed that the cell adhesion molecule 
C-CAM (1 25) represents the same molecule as the rat ecto- 
ATPase described by Lin and Guidotti (33) .  C-CAM was orig- 
inally identified by using antisera in hepatocytes ( 3 3 ,  where 
strongest antibody staining has located it at the membranes 
of bile canaliculi in mature liver ( I  26). C-CAM has also been 
found at relatively high concentrations on the brush border 
of epithelial cells in the mucosa of the small intestine and 
proximal renal tubules, as well as intracellularly in megakar- 
yocytes, platelets, and polymorphonuclear leukocytes (1 26, 
127). This expression pattern is as expected for counterparts 
to the human CEA subgroup, and the derived domain struc- 
tures of the proteins (Fig. 2) support this. These results, 
together with the variable molecular weights found for 
C-CAM isolated from different tissues (123 ,  indicate that 
the antisera used cross-react with different members of the 
rat CEA subgroup. 
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(541, although there is a slight discrepancy between the cal- 
culated and experimentally found molecular weights of the 
polypeptide moiety, which suggests that more than NCA-95 
could exist (Table 3). Due to the high sequence similarity of 
CEA-related proteins and the limited number of accessible 
natural epitopes, it may be expected that it is not possible to 
obtain monoclonal antibodies raised against protein extracts 
which are specific for each antigen. By comparing amino acid 
sequences derived from molecular cloning analyses, regions 
specific to individual antigens can be identified. With this 
information, peptides can be synthesized and used in an 
attempt to generate antigen-specific antisera. This approach 
has been successfully applied in our laboratory for generating 
antisera against the C-domain regions of two PSG products, 
i.e., PSGld and PSG3, and development of further antisera 
is in progress. Similarly, Tsujisaki et al. (128) have raised 
antibodies against CEA peptides, some of which also recog- 
nize purified CEA. 
Other investigations have been performed, or are in prog- 
ress, to locate and better characterize the natural epitopes on 
CEA-related molecules. Although they are heavily glyco- 
sylated, most anti-CEA monoclonal antibodies have been 
shown to bind the polypeptide moiety (15). Mapping has been 
carried out for epitopes on the NCA protein by progressive 
deletion from the C-terminal end of an NCA cDNA clone 
and expression as a fusion protein with the P-galactosidase 
of E .  coli (129). In this manner, two epitopes were mapped 
to the N-terminal domain, one being present on NCA and 
not CEA, and the second is common to both. Site-directed 
mutagenesis was used to determine the exact location of the 
NCA-specific epitope. Using a similar approach, Hass et al. 
(1 30) recently determined the location of different epitopes on 
the CEA polypeptide chain. These authors synthesized the 
four principal domains (N, AIB1, A2B2, and A3B3) and 
expressed them in E.  coli as fusion products with bacterial 
CMP-KDO synthetase. Three groups of monoclonal antibod- 
ies were identified: the first only recognized a single domain, 
the second showed preferential binding to one domain but 
some cross-reactivity with one or more additional domains, 
and the third bound more than one domain equally well. 
An amplification of effectivity in the use of CEA as a tumor 
marker has been achieved by using more than one specific 
antibody for determining serum values as well as for immu- 
nolocalization or immunotherapy purposes (131). For this 
reason it is important to characterize the different epitopes, 
so that competition in binding does not result. In this con- 
text, many laboratories have exchanged their CEA-specific 
antibodies, which have been independently compared by using 
standard reagents (15). The authors compared the reactivity 
of 52 monoclonal antibodies and the results indicate the exis- 
tence of five epitope groups (Gold groups), whereby two 
groups generally show high CEA specificity. Application of 
antibodies from different Gold groups should lead to multi- 
ple CEA binding. This type of multiple binding has the addi- 
For analysis of the proteins encoded by rodent CEA sub- 
group 2 genes (Table 2), antisera have recently been devel- 
oped in our laboratory against a synthetic peptide from the 
derived C-terminal region of the rnCGMl product and against 
the first IgV-like domain. Both antisera recognize a polypep- 
tide with a relative molecular mass (M,) of 120,000- 130,000 
in the supernatant of rnCGMl transfectants, which is of the 
size expected from the derived amino acid sequence data (M, 
75,000) and a calculated M, of 47,000 for the deduced car- 
bohydrate moiety. Independent studies by Ogilvie et al. (122) 
reported on the cross-reactivity of antisera raised against human 
PSG with a major glycoprotein of a similar size (M, 120,000), 
which is present in the basal zone tissue (spongiotrophoblast) 
of rat placenta. These results have been repeated in our labo- 
ratory and it could be confmed that the proteins are identical 
in size. Furthermore, first investigations on the cytochemi- 
cal localization of this protein during placental development 
indicate an exact correlation of its expression pattern with 
that of rnCGMl transcripts. Using our anti-mCGM1 anti- 
sera, this protein has been identified in the blood of pregnant 
female rats, but not in blood from non-pregnant females. Taken 
together, these data confirm that the rodent subgroup 2 genes 
are the counterparts of the human PSG subgroup. 
So far, the rodent subgroup 3 genes have only been par- 
tially characterized at the sequence level and little is known 
about their expression patterns. Indeed, the existence of a 
third subgroup is only based on sequence comparisons, 
because the genes therein cannot be assigned to one of the 
other subgroups. It may be assumed that rnCGM2 and 
mmCGM8 are homologues due to their high sequence simi- 
larities (93% at the nucleotide level in the N1 domain exons). 
IDENTIFICATION OF THE ANTIGENS ENCODED BY 
HUMAN CEA-RELATED GENES 
Although there is evidence that most of the CEA and PSG 
genes are now characterized, identification of the correspond- 
ing antigens still remains a major problem. The present knowl- 
edge regarding such correlations is summarized in Table 3. 
Certainty prevails only in those cases where the antigen has 
been purified and enough protein sequence data exists to allow 
such correlations (i.e., for CEA 180, NCA-50/90, or TEX and 
to a limited extent BGP). Although many CEA-related genes 
have been identified, it still cannot be ruled out that addi- 
tional ones exist and also, a number of molecules described 
as CEA-related probably represent CEA degradation prod- 
ucts, as indicated by amino acid sequencing, e.g., NFA-1, 
NCA-2, and MA-100 (Table 3). 
An alternative approach for identification is to determine 
the reactivity pattern of different, well-characterized mono- 
clonal antibodies with the proteins synthesized by transfectants 
of individual CEA-related cDNAs and to relate this to their 
reactivity pattern to known antigens. Using this method, evi- 
dence would suggest that the CGM6 gene encodes NCA-95 
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tional advantage of avoiding potential problems arising through 
the heterogeneity of CEA from different patients, caused 
mainly by variability in the carbohydrate moieties, which could 
mask epitopes to varying degrees. Taking this into account, 
many of the commercially available CEA-assay kits for deter- 
mining CEA serum levels include mixtures of monoclonal 
anti-CEA antibodies rather than use single ones. 
POST-TRANSLATIONAL MODIFICATIONS OF CEA- 
RELATED ANTIGENS 
One major difficulty regarding the assignment of antigens 
to their mRNAs is caused by post-translational modification 
of CEA-related antigens. It has been known for a long time 
that the CEA family members are heavily glycosylated, and 
the carbohydrate moiety comprises 30% of the total molecu- 
lar weight in PSGs (107) and rises up to 60% in mature CEA 
(reviewed in 11). It may be expected that such heavy 
glycosylation can hinder the binding of antibodies to protein 
epitopes, or be antigenic in itself (15,132). 
The monosaccharide composition of CEA was found to 
contain large amounts of glucosamine, but only negligible 
amounts of galactosamine (1 33,134). This indicates that the 
sugar chains are mostly asparagine linked. As deduced from 
cDNA cloning (95,105,106,135), CEA contains 28 poten- 
tial glycosylation sites. Assuming that all sites are glycosylated, 
and in order to achieve a molecular weight of 180,000, the 
carbohydrate chain length must average 20 monosaccharide 
residues. Analysis of the CEA carbohydrate chains supports 
this calculation, whereby the chains have tetraantennary (80%), 
triantennary (15%), or diantennary (5%) structures (136). 
Kobata et al. (137) have analysed the carbohydrate moieties 
of three CEA samples and an NCA-2 sample (a NCA species 
isolated from meconium). They found differences in the sugar 
chain compositions of these two antigens. Whereas the CEA 
carbohydrate moiety includes high-mannose-type sugar chains, 
this type is absent from NCA-2. Differences in the complex- 
type, outer chain, sugar moieties were also found between 
the two antigens. Nagata et al. (138) recently tested the bind- 
ing affinities of different lectins with CEA isolated from dif- 
ferent tissues. Variability in the major sugar chains was 
determined, depending on the CEA source; i.e., CEA iso- 
lated from the seminal plasma, meconium, and colon adeno- 
carcinomas were all different. This variability is probably due, 
at least in part, to the differences in the fetal and adult 
glycosylation systems (1 39). 
Variability in the degree of glycosylation has also been 
shown for the CEA-related TEX (M, 75,000) and NCA (M, 
45,000) proteins (1 10). It was found by protein sequencing 
and fast bombardment mass spectrometry that the two anti- 
gens have the same protein backbone, corresponding to that 
derived from NCA cDNA clones (105,140,141). In both cases, 
all 12 predicted asparagine-linked glycosylation sites were 
found to be glycosylated. The differences in the molecular 
weights suggest significant variations in their oligosaccha- 
ride structures. These two molecules correspond to NCA-50/ 
90, which has independently been shown by protein sequenc- 
ing to be encoded by the NCA gene (5 1, Table 3). 
A second type of post-translational modification is the 
replacement of the hydrophobic M domain with a glycosyl 
phosphatidylinositol (GPI) moiety, which anchors some mem- 
bers of the human CEA-related subgroup into the plasma mem- 
brane. The relevance of GPI anchorage is unknown, but it is 
a widespread phenomenon for the binding of many membrane 
proteins in eukaryotes (142). These proteins can be released 
from the membrane by digestion with phosphatidylinositol- 
specific phospholipases C or D (PI-PLC, PI-PLD). It is pos- 
sible that the release of CEA into the serum is controlled in 
vivo by such phospholipases, thereby regulating the amount 
of membrane-bound protein. Such a mechanism could explain 
the rapid turnover of CEA in the mucosa of the normal intes- 
tine (100). Furthermore, variability in enzyme activity could 
also explain why for some CEA-producing tumors high serum 
levels are found whereas for others low levels exist, despite 
high CEA concentrations in the tumors (143-145). GPI- 
anchored proteins reveal a more rapid lateral mobility in mem- 
branes than integral membrane proteins, which could have 
functional consequences (reviewed in 142). In addition, GPI- 
anchored proteins are more often found to be located toward 
the apical surface in polarized cells than the basal region, 
which indicates a selective sorting mechanism (146). A spe- 
cial function for the GPI anchor in CEA-related molecules 
remains to be determined. Some CEA-related molecules are 
integral membrane proteins (Fig. 1). Similar variability in the 
type of membrane anchorage has been described for N-CAM 
(147), LFA-3 (148,149), and FcyIII receptors (150). 
A third type of post-translational modification which has 
been reported for CEA-related molecules is phosphorylation. 
Margolis et al. (1 5 1,152) have reported that the rat ecto-ATPase 
is identical to pp120/HA4, which was previously shown to 
be a substrate for the insulin-induced tyrosine kinase (153- 
155). After hormone binding, the intrinsic tyrosine kinase of 
the P-subunit of the insulin receptor is activated and phos- 
phorylates itself (156), as well as several membrane-bound 
and cytosolic substrates (157). Interestingly, the CEA-related 
antigen bearing the CD66 epitope (1 1 1) has been described 
as an M, of 180,000-200,000 phosphorylated protein (1 12). 
REGULATION OF EXPRESSION OF 
CEA-RELATED GENES 
Despite their high sequence similarities, the various mem- 
bers of the CEA family reveal very different expression pat- 
terns, as already discussed. It is of interest to determine what 
regulates this differential expression. In general, it is known 
that regulation of expression can take place at various levels. 
At the basic level, gene amplification has been reported to 
increase the expression of certain genes, e.g., N-myc in neu- 
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The expression patterns exhibited by the human and rodent 
PSG genes indicate coordinated transcriptional activity in the 
placenta (27,61,102). Analyses at the genomic level show 
that the PSG genes are closely linked in humans (61,69) and 
in mouse (32), which could facilitate coordinated expression 
through the use of common regulatory elements. Similar mech- 
anisms may also regulate the expression of the CEA subgroup 
genes (Fig. 3). As discussed, CEA transcripts are often but 
not always coexpressed with NCA transcripts, as shown in 
various tumors. Their direct physical linkage indicates that 
common cis-acting elements may exist there too. For the 
P-globin gene family, it is known that the order of the genes 
within that gene cluster represents the order in which they 
are expressed during ontogenesis (168). Similarly, the posi- 
tional expression pattern of homeotic genes in Drosophila 
and of their mouse counterparts, the Hox genes along the 
anterior/posterior axis of these organisms, has been shown 
to be colinear with the gene order within those clusters (169). 
It will be interesting to see whether variability in the tempo- 
ral or spatial expression patterns of CEA-related molecules 
correlates with their genomic order. Indeed, a differential tem- 
poral expression of mouse subgroup 2 (Table 2) genes dur- 
ing placental development has been found in our laboratory 
(32). Using probes from different cDNA clones, a 3.3 kb 
mRNA species (possibly encoded by mmCGM7) was identi- 
fied in mouse placental extracts from day 11 of gestation, 
but this transcript is drastically reduced at day 13. The situa- 
tion is reversed for two 2.2 kb transcripts (encoded by 
mmCGM5 and mmCGM6), which are not present at day 11 
but appear at day 13. 
Regulation of expression may also occur at the translational 
or post-translational levels. An example for such regulation 
in the CEA family has been documented. Although colonic 
tumors contain on average much higher CEA concentrations 
than the normal colonic mucosa, the steady-state levels of 
CEA transcripts are comparable (10,95,10O,lOl). Using organ 
cultures, Kuroki et al. (100) found that CEA was synthesized 
in equal amounts by normal colon and colonic adenocarci- 
nomas, from which they concluded that CEA has a more rapid 
turnover in normal colon, where it is quickly shed and excreted 
via the feces. In this context, the normal fecal antigens (NFA) 
reported as representing CEA-related molecules (170) prob- 
ably represent CEA breakdown products (Table 3), e.g. ,  the 
N-terminal nine amino acids of NFAl are identical with the 
start of the A2 domain in CEA (170). Thus, the steady-state 
CEA protein levels in colonic tumors are much higher, 
possibly because the CEA cannot be excreted via the intest- 
inal lumen. 
Knowledge of the regulation of expression of CEA is of 
both fundmental and clinical interest. Possibly, stimulating 
CEA expression in vivo would help in binding more CEA- 
specific antibodies at the tumor site for immunolocalization 
or immunotherapeutic purposes. A number of substances have 
been described which up-regulate the expression of CEA- 
roblastomas (1 58), but for CEA-related genes, no evidence 
has so far been found to indicate that this occurs (10,159). 
However, regulation may occur through base modification at 
the DNA level. The degree of DNA methylation in and around 
CEA-related genes has been shown to correlate with CEA 
expression in different cell lines (159). The same authors found 
that tumor cells expressing high amounts of CEA showed 
hypomethylation of CEA-related genes, whereas these genes 
are hypermethylated in normal fibroblast cell lines which do 
not express CEA. 
The next possible level of regulation is at the transcrip- 
tional level. This does play a role for members of the CEA 
family, because transcripts for individual members have only 
been found in certain tissues, indicating either tissue-specific 
transcriptional regulation or differences in the mRNA stabil- 
ities. As a basis for studying regulation at this level, the tran- 
scriptional start sites of two human PSG genes (61,107), the 
CEA and NCA genes (71,106), and two rodent PSG genes, 
rnCGM 1 and mmCGM5 (30,32), have been determined. 
Sequence analysis of the putative promoter regions reveal that 
all these CEA-related genes lack the typical TA'TA- and CAAT- 
box sequences found in many other gene promoters (160). A 
number of genes which also lack TATA boxes have been 
described, including genes which are regulated during differ- 
entiation of mammalian lymphocytes, e.g., 'T-cell receptor 
P-chain genes (161), VPEB gene (162), and the terminal trans- 
ferase gene (163), as well as some Drosophilu homeotic genes 
(1 64- 166). On comparing the sequences of all known CEA- 
related genes upstream from the translational start sites, it is 
obvious that despite relatively high sequence divergence, a 
conserved region exists which correlates with the transcrip- 
tional start sites of a number of these genes. Band-shift anal- 
yses in our laboratory (32) have revealed binding of proteins 
which are apparently ubiquitous to this region, i.e., similar 
binding patterns are found using nuclear extracts from a vari- 
ety of human and rodent tissues or cell lines. This indicates 
that alternative sequences to the TATA box may exist which 
define the transcriptional start sites for CEA-related genes. 
Functional assays were used to determine a cell-type-spe- 
cific promoter region for the CEA gene (71,167). It was found 
that a region located within 112 nucleotides upstream from 
the transcriptional start site is responsible for conveying an 
approximately 10 X higher transcriptional activity in a human 
CEA-producing adenocarcinoma cell line (SW403) compared 
to a non-producing human cell line (HeLa). These results indi- 
cate the presence of an element within the CEA promoter 
which may be responsible for tissue-specific expression, 
although this needs closer examination. 
As mentioned above, higher steady-state levels exist for NCA 
transcripts in colonic tumors compared to the normal colonic 
mucosa. This suggests either an up-regulation of the NCA 
transcription rate or an increased half-life of NCA transcripts 
in tumors. Further studies designed to compare the rates of 
transcription must be carried out before this can be clarified. 
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related molecules in vitro, including several agents known to 
stimulate cellular differentiation, e.g., a-, p-, and y-interferon 
(159,171-174)), theophyllin (175), several polar organic sol- 
vents (176), cyclic AMP (177), sodium butyrate (178-180), 
transforming growth factor (TGF)-pl and 432 (181,182), and 
retinoids (1 83). 
FUNCTIONS OF CEA-RELATED MOLECULES 
One of the most intriguing aspects of the CEA family relates 
to its function(s). Through molecular cloning and analysis of 
the derived protein structures, the relationship to the immu- 
nogobulin supergene family gave first indications regarding 
possible functions. Sequence comparisons of members of this 
superfamily have helped to differentiate two sets of constant- 
like domains, C1 and C2 (39,40). Members of the Cl-set 
are directly involved with immunorecognition, e.g., immu- 
noglobulin heavy and light constant chains, T-cell receptor 
0- and y-chains, as well as major histocompatibility a- and 
0-chains. The C2-set includes a number of cell adhesion mol- 
ecules, e. g . , neural cell adhesion molecule ( 184,185), myelin- 
associated glycoprotein (1 86,187), CD2 (1 88,189), ICAM- 1 
( 190), and ICAM-2 ( 19 1) as well as some cell surface recep- 
tors, e.g., platelet-derived growth factor receptor (192) and 
Fc-receptor (193,194). CEA-related molecules are also 
included in the C2-set and this finding led to directed experi- 
ments to test for cell adhesion functions for chosen CEA 
family members. 
In the meantime, cell adhesion properties have been well 
established in vitro for CEA, NCA, BGP, and the product of 
the rodent gene mmCGM2 (31,90-93). Indeed, in rat, the 
C-CAM molecule was originally isolated because of its adhe- 
sive properties in aggregating hepatocytes (35,195). It is inter- 
esting to note that BGP and mmCGM2 are reportedly 
temperature and calcium dependent in their binding capabil- 
ities (31,93), a property characteristic of the cadherin family 
of adhesion molecules (196,197). CEA and NCA on the other 
hand are neither calcium nor temperature dependent, a fea- 
ture more typical of other immunoglobulin-related adhesion 
molecules (125). Both homophilic (e.g., CEA binding to 
CEA) and heterophilic (e.g., CEA binding to NCA) interac- 
tions have been reported. The adhesive strength, based on 
the speed of aggregation, the final percentage of single cells, 
and the size of the aggregates for a large number of transfec- 
tantsvariesforthesemolecules intheorderCEA>NCA>BGP 
for homophilic interactions (90,93). 
Cell adhesion is known to be important during embryonic 
development, where intercellular interactions occur between 
migrating and fixed cells in the determination of animal form 
during organogenesis (198). Indeed, the expression pattern 
of CEA-related transcripts found in mesenchymal tissues dur- 
ing mouse embryonic development is reconcilable with such 
an in vivo adhesive function for the resulting proteins (123). 
However, a cell adhesion function is difficult to envisage in 
the normal intestine, because CEA is mainly found on the 
brush border toward the lumen (199). Nevertheless, Obrink 
(125) speculates that mouse C-CAM, or C-CAM-related mol- 
ecules (Table 2), which are also located on the microvilli of 
the small intestinal brush border, may be responsible for deter- 
mining the proper organization of these microvilli. 
A similar cell-cell adhesion function for the PSG mole- 
cules is also difficult to imagine because the majority are appar- 
ently not membrane-bound but are secreted instead. Despite 
this, they could mediate binding to cellular matrices. The 
derived amino acid sequences of most but not all PSG pro- 
teins contain the tripeptide sequence arginine-glycine-aspartic 
acid (RGD) in their N-terminal domains, which has been 
reported in a number of substrate adhesion molecules such 
as fibronectin (200) to be responsible for interactions with 
specific receptors on cell membranes. These cells then become 
anchored to the matrix. It remains to be determined if this 
sequence plays a similar role in PSG. Three PSG species 
(PSG1, PSG4, and PSG8) lack this tripeptide sequence, and 
it is noteworthy that they all belong to subclass 1 in Figure 5. 
These molecules may indeed have different or modified func- 
tions relative to the other PSG. The fact that PSG are pro- 
duced at very high levels by the placenta (87) and that low 
serum levels in pregnant women correlate with threatened abor- 
tion (20 1) indicates an important function during pregnancy. 
The suggestion that PSG may protect the developing fetus 
from the maternal immune system is an interesting working 
hypothesis for designing experiments. 
Apart from cellular adhesion, other potential functions have 
recently been proposed for CEA-related molecules. It has been 
reported that both CEA and NCA have a specific affinity for 
binding certain strains of E .  coli bacteria, which are found in 
the human intestinal flora (202). This has been demonstrated 
in vitro and is apparently achieved via a bacterial IectintCEA 
carbohydrate interaction. Such a function is possible for CEA 
only in the normal adult colonic mucosa, which could facili- 
tate bacterial colonization of the intestine. In this context, 
the rapid shedding of CEA into the lumen may represent a 
mechanism for regulating the steady-state level of bacteria pres- 
ent. NCA on the surface of granulocytes could specifically 
bind invading bacteria via this lectintcarbohydrate interaction, 
thus facilitating phagocytosis (202). 
A third possible function is one in which CEA plays an 
accessory role in the in vitro binding of a colonic adenocar- 
cinoma cell line (SW1222) to collagen type I (203), which 
again is hard to envisage in the normal colon. However, in 
migrating embryonic cells as well as metastasizing tumor cells, 
this may be important in mediating interactions with base- 
ment membranes. Furthermore, assuming a similar function 
for NCA, this could have importance in interactions between 
granulocytes and endothelial basement membranes, which are 
necessary before these phagocytic cells can penetrate tissues 
to reach regions of inflammation. 
Sequence homology to a putative rat ecto-ATPase would 
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binding of the antibody by circulating antigen, modulation, 
masking, or loss of the antigen from the tumor cell and immu- 
nogenicity of the heterologous antibodies used (209). In order 
to circumvent at least some of these problems, antibodies can 
be engineered with the help of molecular biological meth- 
ods, without losing their specificity. Experiments along these 
lines have already been carried out for CEA-specific mono- 
clonal antibodies (2 10-2 12). To avoid immunogenicity of the 
antibodies following repeated administration, chimaeric 
monoclonal antibodies have been generated. The murine- 
constant region segments of the H- and L-polypeptides, not 
involved in antigen recognition, were replaced by human 
Ig-constant regions. This type of engineering not only removes 
many murine antigenic determinants but also introduces effec- 
tor recognition regions, e.g., for binding of human comple- 
ment factors, Fc-receptor, etc. In this way, the patient's own 
effector functions could become activated, once antibodies 
are concentrated at the tumor site. 
Another interesting approach which is also based on activa- 
tion of the immune system against tumors involves immu- 
nizing with anti-idiotypic antibodies which mimic a tumor 
antigen, e.g., CEA. This type of immunization should have 
the advantage over immunization with the antigen itself, which 
would lead to the production of antisera recognizing not only 
CEA, but also all crossreacting antigens. For immunization, 
antibodies specific for CEA could be used, thus circumvent- 
ing these problems. Tsujisaki et al. (213) reported the 
development of such anti-idiotypic antibodies, which were 
indeed recognized by polyclonal antisera raised against CEA. 
Similar results have also been reported by two other groups 
(214,215). 
The animal model system should help with preclinical trials 
for testing the efficacy of monoclonal antibodies in the immu- 
notherapy of CEA-producing tumors. Once regulatory regions 
have been determined, which direct the expression of CEA 
in colonic tissues, constructs may be utilized for making 
transgenic mice, whereby induced colonic tumors should 
express human CEA. Different antibodies could be tested indi- 
vidually or in combination, and also together with other types 
of therapy, so that the optimal approach can be developed in 
vivo, prior to application in cancer patients. Furthermore, the 
expression of CEA could be up-regulated by addition of dif- 
ferent substances known to have this effect in vivo, in an 
attempt to increase its concentration and thereby the concen- 
tration of labelled anti-CEA antibodies at the tumor site. 
Therefore, although much work still remains to be done, 
the foundations have been laid for the directed use of CEA- 
related molecules in the fight against cancer, and further 
experimentation should help to optimize their applications 
for the future. 
suggest a possible enzymatic function for members of the CEA 
family (33). Such a function could regulate the adhesive prop- 
erties of CEA-related molecules, as the rat ecto-ATPase was 
found to be identical to C-CAM (124), which was described 
as responsible for the adhesion of aggregating rat hepatocytes 
(35). It is noteworthy that the addition of exogenous ATP has 
been reported to inhibit, whereas ADP stimulated aggrega- 
tion of mouse liver cells (204). Furthermore, granulocytes 
can secrete ATP with which they could regulate their own 
adhesive properties (205). 
Most of the above functions have been determined in vitro 
but remain to be confirmed in vivo. Such investigations can- 
not be carried out in humans, but the animal model offers 
possibilities, e.g., through inhibition of specific gene expres- 
sion by homologous recombination with defective gene con- 
structs in transgenic mice (206). Any ensuing phenotypic 
abnormalities could help in understanding the in vivo functions. 
Finally, the role of CEA in directing metastases from 
colorectal cancers to &he liver has also been discussed (reviewed 
in 207). Hostetter et al. (208) showed that after transplanta- 
tion of human colorectal tumors in athymic nude mice, the 
number of liver metastases increased from 2% to 48% on 
preinjection of the mice with CEA. A possible explanation 
for this is the binding of CEA via a specific receptor known 
to exist on Kupffer cells (88,891 and a homophilic binding 
of this CEA with CEA on the surface of metastatic colorectal 
tumor cells, which then become immobilized and develop 
secondary tumors (207). 
CLINICAL OUTLOOK 
Based on the data gained so far, a number of methods are 
available which should help to determine more exactly as well 
as increase the clinical reliability of CEA. Existing antibod- 
ies are in the process of being tested for specificity against 
panels of transfectants expressing individual CEA-related mol- 
ecules. With the development of anti-CEA antibodies raised 
against synthetic peptides, this should increase the availabil- 
ity of defined antibodies. Furthermore, it is becoming obvi- 
ous that other members of the CEA family may also be useful 
as tumor markers, e.g., NCA in colonic tumors. It may be 
that the combined expression pattern of more than one mem- 
ber of the CEA family could be utilized for diagnosis of tumors 
of unknown origin when interpretation of histological data is 
difficult, as well as in the determination of whether a tumor 
is benign or malignant providing that variability of expres- 
sion exists. Before such questions can be answered, however, 
statistical evaluation of the expression patterns for the differ- 
ent family members must be carried out, e.g., by polymer- 
ase chain reaction combined with in situ hybridization data 
and immunohistology. 
The usefulness of specific antibodies for immunolocalization 
or for immunotherapy is already obvious, although other prob- 
lems also exist, e.g., uptake of antibodies in unwanted cells, 
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